doxazosin has been researched along with Chronic Kidney Diseases in 2 studies
Doxazosin: A prazosin-related compound that is a selective alpha-1-adrenergic blocker.
doxazosin : A member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Meremo, A | 1 |
| Paget, G | 1 |
| Duarte, R | 1 |
| Dickens, C | 1 |
| Dix-Peek, T | 1 |
| Bintabara, D | 1 |
| Naicker, S | 1 |
| Yasuda, G | 1 |
| Saka, S | 1 |
| Ando, D | 1 |
| Hirawa, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Doxazosin on Ambulatory Blood Pressure and Sympathetic Nervous Activity in Hypertensive Patients With Diabetic Nephropathy[NCT00295555] | Phase 4 | 98 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for doxazosin and Chronic Kidney Diseases
| Article | Year |
|---|---|
Effects of doxazosin as the third agent on morning hypertension and position-related blood pressure changes in diabetic patients with chronic kidney disease.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulat | 2015 |
1 other study available for doxazosin and Chronic Kidney Diseases
| Article | Year |
|---|---|
Demographic and clinical profile of black patients with chronic kidney disease attending a tertiary hospital in Johannesburg, South Africa.
Topics: Acidosis; Aged; Allopurinol; Anemia; Bicarbonates; Cross-Sectional Studies; Diabetes Mellitus; Doxaz | 2022 |